AFJK Financials Aimei Health Technology Co., Ltd.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | $1M | — | — | -26.1% | 8.8% | — | — | — |
| 2024 | — | $3M | — | — | -172.8% | 3.5% | — | — | — |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$83144 | — | — | 1.9% | -0.7% | — | — | — |
| Mar '26 | — | $45440 | — | — | -1.1% | 0.4% | — | — | — |
| Dec '25 | — | $98117 | — | — | -2.4% | 0.8% | — | — | — |
| Sep '25 | — | $352019 | — | — | -10.2% | 0.8% | — | — | — |
| Jun '25 | — | $424970 | — | — | -14.9% | 1.0% | — | — | — |
| Mar '25 | — | $184662 | — | — | -7.8% | 0.4% | — | — | — |
| Dec '24 | — | $444113 | — | — | -30.1% | 0.6% | — | — | — |
| Sep '24 | — | $743510 | — | — | -93.3% | 1.0% | — | — | — |
| Jun '24 | — | $609092 | — | — | -102.0% | 0.8% | — | — | — |
| Mar '24 | — | $755500 | — | — | -262.5% | 1.1% | — | — | — |
| Dec '23 | — | $175007 | — | — | -130.5% | 0.2% | — | — | — |
| Sep '23 | — | $0 | — | — | 0.0% | — | — | — | — |
| Jun '23 | — | -$3618 | — | — | 100.0% | — | — | — | — |
Valuation over time
How the market has priced AFJK against its own fundamentals since 2024-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 13.2× (Dec '24) to 36.6× (Nov '26).
Frequently asked questions
Is AFJK growing its revenue and profit?
See the revenue and net-income charts above for Aimei Health Technology Co., Ltd.'s multi-year trend.
How much debt does AFJK have?
As of FY2025, Aimei Health Technology Co., Ltd. reported — of total debt against — of cash.
What is AFJK's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is AFJK's P/E ratio?
Aimei Health Technology Co., Ltd.'s P/E (TTM) is 94.12 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the AFJK stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 36.6× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.